Area of research
Surgery · Radiation
Research interest
Research interests include Colorectal and Anal Carcinomas, Advanced Radiotherapy Techniques, Colorectal Cancer Surgical Treatments, and Gastric Cancer Management and Outcomes.
Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma.
Incidence of breast implant–associated anaplastic large cell lymphoma
NEO-RT Organ Preservation Trial for Early Rectal Cancer: CCTG CO.32 Phase III Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus Chemoradiotherapy
Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003.
Patient-Reported Outcomes During Pelvic Radiation Therapy: A Secondary Analysis on Sexual Function From NRG-RTOG 1203.
Results of a phase II trial of short-course radiation and TASOX [trifluridine/tipiracil (TAS-102) plus oxaliplatin] chemotherapy in operable rectal cancer.
Supplementary Figures S1-S6 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Supplementary Tables S1-S3 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Management of Locally Advanced Rectal Cancer: ASCO Guideline
Management of Locally Advanced Rectal Cancer: ASCO Guideline.
Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.
Stereotactic Radiosurgery vs Conventional Radiotherapy for Localized Vertebral Metastases of the Spine
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors
MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.
Prognosis and risk of suicide after cancer diagnosis
Supplementary Tables S1-S3 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Data from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Data from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Supplementary Figures S1-S6 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Supplementary Figures S1-S6 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Supplementary Tables S1-S3 from <i>MGMT</i> Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas
Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium
Intensity-Modulated Radiation Therapy Reduces Patient-Reported Chronic Toxicity Compared With Conventional Pelvic Radiation Therapy: Updated Results of a Phase III Trial.
Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.
NRG-CC008: A nonrandomized prospective clinical trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers [SOROCk].
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
Improvement in Patient-Reported Outcomes With Intensity-Modulated Radiotherapy (RT) Compared With Standard RT: A Report From the NRG Oncology RTOG 1203 Study
NRG Oncology CC001: A phase III trial of hippocampal avoidance (HA) in addition to whole-brain radiotherapy (WBRT) plus memantine to preserve neurocognitive function (NCF) in patients with brain metastases (BM).